TAKEDA-PHARMACEUTICAL
10.5.2016 08:03:15 CEST | Business Wire | Press release
Takeda Pharmaceutical Company Limited (TOKYO:4502):
| FY2015: A year of turnaround to sustained growth; achieved full year management guidance | |||
|
• |
Underlying revenue up +3.4% (reported revenue growing +1.7% to 1,807.4 billion yen), led by strong performances in Takeda's growth drivers (GI, Oncology, CNS and Emerging Markets) |
||
|
• |
Underlying Core Earnings up +8.1% (reported operating profit recorded 130.8 billion yen), aided by cost discipline |
||
|
• |
Underlying Core EPS up +21.7% (reported EPS was 102 yen), growing 2.5x faster than underlying core earnings |
||
| Growth Drivers continued to be robust | |||
|
• |
Consolidated underlying revenue growth of Gastroenterology (GI), Oncology, Central Nervous System (CNS) and Emerging Markets – Takeda's Growth Drivers – was +9.5% year-to-year |
||
|
• |
Underlying revenue of GI +23.6%, Oncology +1.0%* and CNS +37.3% year-to-year |
||
|
• |
Emerging Markets underlying revenue +4.8% year-to-year with continued growth in the key markets of China, Russia and Brazil |
||
|
*Underlying growth of Oncology excluding VELCADE royalties was +4.4% |
|||
|
Broad portfolio of growing products offsets loss of exclusivity decline |
|||
|
• |
ENTYVIO(®) is on track to exceed $2 billion MAT* sales within FY2018 |
||
|
• |
Encouraging uptake of NINLARO(®) and TAKECAB(®) |
||
|
• |
BRINTELLIX(®) and ADCETRIS(®) showed continued growth |
||
|
• |
AZILVA(®) and LOTRIGA(®) are contributing to the Japan business |
||
|
*Moving Annual Total @ constant currency |
|||
| Efficiency gains continue | |||
|
• |
Project Summit well exceeded full-year target resulting in 30 billion yen additional cost savings |
||
|
• |
Strong cash flow performance with Operating Free Cash Flow, excluding Actos settlement payment, reaching 230 billion JPY |
||
| FY2016 management guidance: A year of strategic focus to sustain growth | |||
|
• |
Underlying Revenue: Mid-single digit growth (%) |
||
|
• |
Underlying Core Earnings: Low- to mid-teen growth (%) |
||
|
• |
Underlying Core EPS: Low- to mid-teen growth (%) |
||
Christophe Weber, President and Chief Executive Officer of Takeda,
commented:
"FY2015 was a turnaround year. We achieved our
management guidance for the second consecutive year, led by our growth
drivers, and aided by the global launches of new products such as
ENTYVIO and NINLARO. Takeda will continue to deliver innovative new
medicines to patients, especially in our focused R&D therapeutic areas.
Takeda aims to relentlessly execute our strategic roadmap to deliver our
long-term aspiration, and will serve the needs of the patients, with the
best in class agility and innovation."
|
|
|||||||||
|
Key figures for the full |
year of FY2015 (April 2015 –March 2016) |
||||||||
| FY 2014 | FY 2015 | Growth | |||||||
| (billion yen) | Underlying2 | ||||||||
| Revenue | 1,777.8 | 1,807.4 | +1.7% | +3.4% | |||||
| Operating Profit | -129.3 | 130.8 | – | – | |||||
| Core Earnings 1 | 288.3 | 292.4 | +1.4% | +8.1% | |||||
| Net Profit 3 | -145.8 | 80.2 | – | – | |||||
| EPS | -185 yen | 102 yen | – | – | |||||
| Core EPS | 225 yen | 258 yen | +14.8% | +21.7% | |||||
|
1 |
Core Earnings is calculated from operating profit by excluding the impact of exceptional items, such as purchase accounting, amortization and impairment loss of intangible assets, restructuring costs and major litigation costs. | |
|
2 |
Underlying performance aims at understanding the real performance of the business. Underlying Revenue, Underlying Core Earnings, and Underlying Core EPS exclude the same as above and adjusted for acquisitions/divestments and foreign exchange. | |
|
3 |
Attributable to the owners of the company | |
Underlying revenue growth was mainly driven by Takeda's Growth Drivers: Gastroenterology(GI), Oncology, and Central Nervous System (CNS) in addition to Emerging Markets. The Growth Drivers account for 52% of Takeda's revenue. GI revenue grew by +23.6% year-to-year, driven by ENTYVIO® . Oncology revenue increased by +1.0%, contributed by VELCADE® , ADCETRIS® and NINLARO® , which has shown an encouraging start in the U.S. since it was launched in December,. Oncology revenue excluding VELCADE royalties grew +4.4%. CNS revenue, including BRINTELLIX® , increased by +37.3%. Emerging Markets revenue grew by +4.8% year-to-year, led by Value Brands (branded generics and Over-The-Counter medicines), with steady growth in China (+11.1%), Russia (+6.2%) and Brazil (+5.7%). However, our future aspiration for growth in Emerging Markets remains strong, in high single digits. Performance in the U.S. (+12.4% year-to-year underlying revenue growth) also contributed to total revenue growth. In Japan, which remains under increasing generic pressure, underlying revenue declined -3.3% year-to-year, but AZILVA® and LOTRIGA® showed significant sales growth of +30.1% and +69.0%, respectively, year-to-year. In addition to these growing products, TAKECAB® and ZAFATEK® are expected to be key sales drivers in Japan after the lifting of the 2-week limit on the prescription period.
Consolidated operating profit was 130.8 billion yen, an increase of 260.1 billion yen compared to the previous year, which exceeded the raised forecast of 120 billion yen announced in February at the FY2015 3rd quarter earnings announcement. Selling, general and administrative expenses increased by 38.2 billion yen (+6.2%) compared to the previous year, mainly due to the increase in sales expenses related to new products in the U.S., but R&D expenses decreased by 36.2 billion yen (-9.5%). Amortization and impairment losses on intangible assets associated with products decreased by 51.3 billion yen (-29.1%), mainly due to 30.5 billion yen of COLCRYS® impairment loss being recognized in 2014 compared to an 8.6 billion yen impairment reversal in fiscal 2015. Other operating income decreased by 82.1 billion yen (-76.6%), mainly due to 53.8 billion yen of revaluation of COLCRYS® contingent consideration liability and 32.8 billion yen of the gains on sales of real estate being recognized in the previous year. Other operating expenses decreased by 277.8 billion yen (-86.2%), mainly due to 274.1 billion yen of loss on Actos litigation in the U.S. being recognized in the previous year.
Project Summit – a company-wide strategic initiative to increase efficiency – continued to produce results, with 30 billion yen of additional savings in FY2015, exceeding the full year target as a result of higher Procurement savings.
As part of its ongoing effort to improve R&D productivity, Takeda is focusing on its core therapeutic areas of Oncology, GI and CNS. Takeda will further strengthen its initiatives and commitment to lead innovation in medicines and provide innovative new drugs to patients around the world including in emerging markets.
FY2015 was positioned for Takeda as a year of turnaround to sustained growth, and Takeda sets the following management guidance for FY2016 as a year of strategic focus to sustain growth.
|
Management Guidance for FY2016 |
|||
| Underlying Growth (%) | |||
| Underlying Revenue | Mid-single digit | ||
| Underlying Core Earnings | Low- to mid-teen | ||
| Underlying Core EPS | Low- to mid-teen | ||
| Dividend per Share | 180 yen | ||
|
Reported Forecast for FY2016 |
(change vs. FY2015 results) |
|||
| billion yen | FY 2016 1 | Change | ||
| Revenue | 1,720.0 | -4.8% | ||
| R&D expenses | 325.0 | -6.0% | ||
| Operating Profit | 135.0 | +3.2% | ||
| Net Profit 2 | 88.0 | +9.8% | ||
| EPS | 112 yen | +9.8% | ||
| 1 | The exchange rate assumptions for FY2016 are 1US$=110 yen and 1 euro=125 yen | |
| 2 | Attributable to the owners of the company | |
For more details on Takeda’s FY2015 full year results and other financial information, please visit http://www.takeda.com/investor-information/results/
About Takeda Pharmaceutical Company Limited
Takeda
Pharmaceutical Company Limited (TOKYO:4502
)
is a global, R&D-driven pharmaceutical company committed to bringing
better health and a brighter future to patients by translating science
into life-changing medicines. Takeda focuses its research efforts on
oncology, gastroenterology and central nervous system therapeutic areas.
It also has specific development programs in specialty cardiovascular
diseases as well as late-stage candidates for vaccines. Takeda conducts
R&D both internally and with partners to stay at the leading edge of
innovation. New innovative products, especially in oncology, central
nervous system and gastroenterology, as well as its presence in emerging
markets, fuel the growth of Takeda. More than 30,000 Takeda employees
are committed to improving quality of life for patients, working with
our partners in health care in more than 70 countries. For more
information, visit http://www.takeda.com/news
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160509006801/en/
Contact:
Takeda Pharmaceutical Company Limited
Investor Relations
Noriko
Higuchi, +81-(0)3-3278-2306
noriko.higuchi@takeda.com
or
Media
Relations
Japanese media
Tsuyoshi Tada, +81
(0)3-3278-2417
tsuyoshi.tada@takeda.com
or
Media
outside Japan
Jocelyn Gerst, +1-224-554-5542
jocelyn.gerst@takeda.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
teamLab Biovortex Kyoto to Open 'Teahouse in a Sea of Light' for Savoring Tea. On View from Friday, November 20. Artworks Including Tea in Spontaneous Order on View20.11.2026 07:00:00 CET | Press release
teamLab Biovortex Kyoto opens ‘Teahouse in a Sea of Light’ on Friday, November 20, 2026, where visitors can savor tea within the Sea of Solidified Light. Artworks exhibited in the teahouse, including Tea in Spontaneous Order, are now unveiled. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117922442/en/ Aged Coffee Tonic, Tea in Spontaneous Order, 2021- ©︎ teamLab *Shot in real space. No AI or CGI. *No Artificial Colors Teahouse in a Sea of Light A space for savoring tea within a sea of light. When a cup of tea is made, the artwork is born. The tea interacts with nearby tea and the sea of light, creating a time structure throughout the entire space of the artwork. Visitors drink part of this formed order itself. Coinciding with the opening of ‘Teahouse in a Sea of Light,’ Pocket Garden of Eternal Existence is newly unveiled at the museum's entrance gate. teamLab Biovortex Kyoto teamLab Biovortex Kyoto is teamLab's largest
OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 17:30:00 CET | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac
ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 16:24:00 CET | Press release
Refreshed framework reflects today’s technology landscape with streamlined design guidance, refreshed objectives and three levels of organizational assessment When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technolo
North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 16:04:00 CET | Press release
Microsoft-backed Saskatchewan project developed by MLTC and Svante among only three BECCS projects selected North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioene
Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 15:32:00 CET | Press release
Developers Can Now Reach Players on Desktop and the Web With Xsolla Player and Xsolla Pages Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally req
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
